A recent BMJ Open trial introduces the iRITUX protocol—an AI-driven approach to tailor rituximab dosing in membranous nephropathy. Researchers, including Teisseyre and Destere, conducted the study across 13 French hospitals. By predicting underdosing risks early, the protocol refines treatment, improving clinical remission. This work highlights AI’s potential to customize therapies in chronic kidney disorders.
Q&A
- What is the iRITUX trial?
- How does the machine learning algorithm function?
- What are the primary outcomes measured?